Preoperative Patient-Reported Outcomes in Suspected Low-Grade Glioma: Markers of Disease Severity and Correlations with Molecular Subtypes
Abstract
:1. Introduction
2. Materials and Methods
2.1. Assessment of Molecular Status
2.2. Assessment of Preoperative Health-Related Quality of Life
2.3. Assessment of Preoperative Fatigue
2.4. Assessment of Preoperative Psychological Distress
2.5. Statistical Analysis
3. Results
3.1. Preoperative HRQoL and Functioning in Patients with Suspected dLGG and by Molecular Subtype
3.2. Preoperative Fatigue Based on MFI and the Fatigue Scale of QLQ-C30
3.3. Preoperative Anxiety and Depression
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Pignatti, F.; van den Bent, M.; Curran, D.; Debruyne, C.; Sylvester, R.; Therasse, P.; Áfra, D.; Cornu, P.; Bolla, M.; Vecht, C.; et al. Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma. J. Clin. Oncol. 2002, 20, 2076–2084. [Google Scholar] [CrossRef]
- Reijneveld, J.C.; Sitskoorn, M.M.; Klein, M.; Nuyen, J.; Taphoorn, M.J. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology 2001, 56, 618–623. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rudà, R.; Trevisan, E.; Soffietti, R. Epilepsy and brain tumors. Curr. Opin. Oncol. 2010, 22, 611–620. [Google Scholar] [CrossRef]
- Danfors, T.; Ribom, D.; Berntsson, S.G.; Smits, A. Epileptic seizures and survival in early disease of grade 2 gliomas. Eur. J. Neurol. 2009, 16, 823–831. [Google Scholar] [CrossRef]
- Whittle, I.R. The dilemma of low grade glioma. J. Neurol. Neurosurg. Psychiatry 2004, 75 (Suppl. 2), ii31–ii36. [Google Scholar] [CrossRef] [Green Version]
- Cancer Genome Atlas Research Network; Brat, D.J.; Verhaak, R.G.W. Faculty Opinions recommendation of Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 2015, 372, 2481–2498. [Google Scholar] [CrossRef] [Green Version]
- Louis, D.N.; Perry, A.; Reifenberger, G.; Von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016, 131, 803–820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van den Bent, M.J. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician’s perspec-tive. Acta Neuropathol. 2010, 120, 297–304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coons, S.W.; Johnson, P.C.; Scheithauer, B.W.; Yates, A.J.; Pearl, D.K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997, 79, 1381–1393. [Google Scholar] [CrossRef]
- van den Bent, M.J.; Brandes, A.A.; Taphoorn, M.J.B.; Kros, J.M.; Kouwenhoven, M.C.M.; Delattre, J.-Y.; Bernsen, H.J.J.A.; Frenay, M.; Tijssen, C.C.; Grisold, W.; et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31, 344–350. [Google Scholar] [CrossRef] [PubMed]
- Cairncross, J.G.; Wang, M.; Shaw, E.; Jenkins, R.; Brachman, D.; Buckner, J.; Fink, K.; Souhami, L.; Laperriere, N.; Curran, W.; et al. Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. J. Clin. Oncol. 2013, 31, 337–343. [Google Scholar] [CrossRef]
- Buckner, J.C.; Shaw, E.G.; Pugh, S.L.; Chakravarti, A.; Gilbert, M.R.; Barger, G.R.; Coons, S.; Ricci, P.; Bullard, D.; Brown, P.D.; et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N. Engl. J. Med. 2016, 374, 1344–1355. [Google Scholar] [CrossRef] [PubMed]
- van Coevorden-van Loon, E.M.P.; Coomans, M.B.; Heijenbrok-Kal, M.H.; Ribbers, G.M.; van den Bent, M.J. Fatigue in patients with low grade glioma: Systematic evaluation of assessment and prevalence. J. Neurooncol. 2017, 133, 237–246. [Google Scholar] [CrossRef] [Green Version]
- Gustafsson, M.; Edvardsson, T.; Ahlström, G. The relationship between function, quality of life and coping in patients with low-grade gliomas. Support. Care Cancer 2006, 14, 1205–1212. [Google Scholar] [CrossRef]
- Cheng, J.-X.; Liu, B.-L.; Zhang, X.; Lin, W.; Zhang, Y.-Q.; Liu, W.-P.; Zhang, J.-N.; Lin, H.; Wang, R.; Yin, H. Health-related quality of life in glioma patients in China. BMC Cancer 2010, 10, 305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schei, S.; Solheim, O.; Jakola, A.S.; Sagberg, L.M. Perioperative fatigue in patients with diffuse glioma. J. Neuro-Oncol. 2020, 147, 97–107. [Google Scholar] [CrossRef] [Green Version]
- Struik, K.; Klein, M.; Heimans, J.J.; Gielissen, M.F.; Bleijenberg, G.; Taphoorn, M.J.; Reijneveld, J.C.; Postma, T.J. Fatigue in low-grade glioma. J. Neuro-Oncol. 2008, 92, 73–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Skjulsvik, A.J.; Bø, H.K.; Jakola, A.S.; Berntsen, E.M.; Bø, L.E.; Reinertsen, I.; Myrmel, K.S.; Sjåvik, K.; Åberg, K.; Berg, T.; et al. Is the anatomical distribution of low-grade gliomas linked to regions of gliogenesis? J. Neuro-Oncol. 2020, 147, 147–157. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Zhang, T.; Li, S.; Fan, X.; Ma, J.; Wang, L.; Jiang, T. Anatomical localization of isocitrate dehydrogenase 1 mutation: A voxel-based radiographic study of 146 low-grade gliomas. Eur. J. Neurol. 2014, 22, 348–354. [Google Scholar] [CrossRef]
- Gustin, A.N., Jr. Shared Decision-Making. Anesthesiol. Clin. 2019, 37, 573–580. [Google Scholar] [CrossRef]
- Chang, E.F.; Smith, J.S.; Chang, S.M.; Lamborn, K.R.; Prados, M.D.; Butowski, N.; Barbaro, N.M.; Parsa, A.T.; Berger, M.S.; McDermott, M.M. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J. Neurosurg. 2008, 109, 817–824. [Google Scholar] [CrossRef] [Green Version]
- Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N.J.; Filiberti, A.; Flechtner, H.; Fleishman, S.B.; De Haes, J.C.; et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. J. Natl. Cancer Inst. 1993, 85, 365–376. [Google Scholar] [CrossRef]
- Osoba, D.; Aaronson, N.K.; Muller, M.; Sneeuw, K.; Hsu, M.-A.; Yung, W.K.A.; Brada, M.; Newlands, E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual. Life Res. 1996, 5, 139–150. [Google Scholar] [CrossRef]
- The EuroQol Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy 1990, 16, 199–208. [Google Scholar] [CrossRef]
- Dolan, P. Modeling Valuations for EuroQol Health States. Med. Care 1997, 35, 1095–1108. [Google Scholar] [CrossRef]
- Smets, E.M.A.; Garssen, B.; Bonke, B.; De Haes, J.C.J.M. The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 1995, 39, 315–325. [Google Scholar] [CrossRef] [Green Version]
- Hagelin, C.L.; Wengström, Y.; Runesdotter, S.; Fürst, C.J. The psychometric properties of the Swedish Multidimensional Fatigue Inventory MFI-20 in four different populations. Acta Oncol. 2007, 46, 97–104. [Google Scholar] [CrossRef]
- Giesinger, J.M.; Kuijpers, W.; Young, T.; Tomaszewski, K.A.; Friend, E.; Zabernigg, A.; Holzner, B.; Aaronson, N.K. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: Physical functioning, emotional functioning, fatigue and pain. Health Qual. Life Outcomes 2016, 14, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zigmond, A.S.; Snaith, R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 1983, 67, 361–370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smith, R.; Zigmond, A. The Hospital Anxiety and Depression Scale Manual; NFER-Nelson: Windsor, UK, 1994. [Google Scholar]
- Fayers, P.A.N.K.; Bjordal, K.; Groenvold, M.; Curran, D.; Bottomley, A. EORTC QLQ-C30 Scoring Manual, 3rd ed.; European Organisation for Research and Treatment of Cancer: Brussels, Belgium, 2001. [Google Scholar]
- Burström, K.; Johannesson, M.; Diderichsen, F. Swedish population health-related quality of life results using the EQ-5D. Qual. Life Res. 2001, 10, 621–635. [Google Scholar] [CrossRef]
- Engberg, I.; Segerstedt, J.; Waller, G.; Wennberg, P.; Eliasson, M. Fatigue in the general population- associations to age, sex, socioeconomic status, physical activity, sitting time and self-rated health: The northern Sweden MONICA study 2014. BMC Public Health 2017, 17, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Breemen, M.S.; Wilms, E.B.; Vecht, C.J. Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and manage-ment. Lancet Neurol. 2007, 6, 421–430. [Google Scholar] [CrossRef]
- Cochereau, J.; Herbet, G.; Rigau, V.; Duffau, H. Acute progression of untreated incidental WHO Grade II glioma to glioblastoma in an asymptomatic patient. J. Neurosurg. 2016, 124, 141–145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jakola, A.S.; Sagberg, L.M.; Gulati, S.; Solheim, O. Advancements in predicting outcomes in patients with glioma: A surgical per-spective. Expert Rev. Anticancer Ther. 2020, 20, 167–177. [Google Scholar] [CrossRef] [PubMed]
- Lisspers, J.; Nygren, A.; Söderman, E. Hospital Anxiety and Depression Scale (HAD): Some psychometric data for a Swedish sample. Acta Psychiatr. Scand. 1997, 96, 281–286. [Google Scholar] [CrossRef]
- D’Angelo, C.; Mirijello, A.; Leggio, L.; Ferrulli, A.; Carotenuto, V.; Icolaro, N.; Miceli, A.; D’Angelo, V.; Gasbarrini, G.; Addolorato, G. State and trait anxiety and depression in patients with primary brain tumors before and after surgery: 1-year longitudinal study. J. Neurosurg. 2008, 108, 281–286. [Google Scholar] [CrossRef] [Green Version]
Characteristic | All (n = 51) | IDHwt Astrocytomas (n = 16) | IDHmut Astrocytomas (n = 18) | Oligodendrogliomas (n = 17) |
---|---|---|---|---|
Age, mean (SD) | 49 (14) | 56 (12) | 41 (14) | 50 (13) |
Sex, No. (%) | ||||
Male | 32 (63) | 11 (69) | 11 (61) | 10 (59) |
Female | 19 (37) | 5 (31) | 7 (39) | 7 (41) |
Tumor location, No. (%) | ||||
Frontal | 23 (45) | 7 (47) | 6 (33) | 10 (59) |
Temporal | 12 (24) | 5 (33) | 6 (33) | 1 (6) |
Parietal | 5 (10) | 0 (0) | 4 (22) | 1 (6) |
Insula | 6 (12) | 1 (7) | 2 (11) | 3 (18) |
Others 1 | 5 (10) | 3 (19) | 0 (0) | 2 (12) |
Lateralization, No. (%) | ||||
Left | 24 (47) | 8 (53) | 12 (67) | 4 (24) |
Right | 25 (49) | 6 (40) | 6 (33) | 13 (76) |
Bilateral/midline | 2 (4) | 2 (13) | 0 (0) | 0 (0) |
Multifocal lesions, No. (%) | 8 (16) | 5 (31) | 1 (6) | 2 (12) |
Eloquent location, No. (%) | 35 (69) | 12 (75) | 13 (72) | 10 (59) |
Histologic type and grade, No. (%) | ||||
Grade II | 31 (61) | 8 (50) | 14 (78) | 9 (53) |
Grade III | 16 (31) | 6 (38) | 2 (11) | 8 (47) |
Grade IV | 4 (8) | 2 (12) | 2 (11) | 0 (0) |
AED treatment, No. (%) | 35 (69) | 13 (81) | 12 (67) | 10 (59) |
Antidepressants, No. (%) | ||||
SSRI | 3 (6) | 1 (7) | 1 (9) | 1 (6) |
Tricyclic antidepressants | 2 (4) | 0 (0) | 1 (9) | 1 (6) |
Anxiolytic/Hypnotics, No. (%) | ||||
Benzodiazepines | 7 (14) | 3 (20) | 2 (11) | 2 (12) |
Zopiclone | 22 (43) | 8 (50) | 7 (39) | 7 (41) |
Others 2 | 3 (6) | 0 (0) | 2 (11) | 1 (6) |
All (n = 51) | IDHwt Astrocytomas (n = 16) | IDHmut Astrocytomas (n = 18) | Oligodendrogliomas 1 (n = 17) | p-Value 2 | p-Value 3 | |
---|---|---|---|---|---|---|
Functioning—EORTC QLQ-C30 | ||||||
Physical functioning | 81 (20) | 76 (17) | 82 (18) | 84 (25) | 0.16 | 0.09 |
Role functioning | 55 (35) | 42 (38) | 59 (29) | 64 (38) | 0.18 | 0.07 |
Emotional functioning | 63 (27) | 58 (24) | 61 (28) | 71 (27) | 0.30 | 0.28 |
Cognitive functioning | 68 (29) | 57 (30) | 69 (25) | 77 (29) | 0.10 | 0.06 |
Social functioning Symptom domains—EORTC QLQ-BN20 | 66 (31) | 62 (28) | 63 (34) | 75 (32) | 0.26 | 0.26 |
Future uncertainty | 59 (25) | 52 (26) | 61 (25) | 64 (23) | 0.39 | 0.19 |
Visual disorder | 13 (20) | 10 (17) | 19 (26) | 8 (14) | 0.39 | 0.57 |
Motor dysfunction | 19 (25) | 30 (30) | 14 (18) | 13 (24) | 0.14 | 0.06 |
Communication deficit | 20 (26) | 28 (31) | 18 (23) | 13 (23) | 0.10 | 0.06 |
Psychological distress 4 | ||||||
HADS—anxiety, median (IQR) | 8 (4–10.5) | 9 (4–12) | 7 (4–10) | 9 (4–11) | 0.62 | 0.68 |
HADS—depression, median (IQR) | 3 (1–7) | 5 (2–8) | 4 (1–7) | 1 (1–7) | 0.44 | 0.29 |
HRQoL | ||||||
EQ-5D-3L index—overall health 5 | 0.67 (0.3) | 0.61 (0.25) | 0.67 (0.3) | 0.73 (0.33) | 0.34 | 0.14 |
EQ-VAS 5 | 61 (27) | 59 (33) | 65 (23) | 58 (26) | 0.77 | 0.98 |
QLQ-C30—global health status | 55 (24) | 50 (25) | 55 (24) | 61 (25) | 0.41 | 0.41 |
Characteristic | High Fatigue (n = 23) | Low Fatigue (n = 27) | p-Value 2 |
---|---|---|---|
Age, mean (SD) | 47 (15) | 50 (14) | 0.51 |
Sex, No. (%) | 0.03 | ||
Male | 11 (42) | 21 (78) | |
Female | 12 (52) | 6 (22) | |
Tumor location, No. (%) | 0.81 | ||
Frontal | 11 (48) | 12 (44) | |
Temporal | 6 (26) | 6 (22) | |
Parietal | 1 (4) | 3 (11) | |
Insula | 2 (9) | 4 (15) | |
Others 3 | 3 (13) | 2 (7) | |
Lateralization, No. (%) | 0.14 | ||
Left | 9 (39) | 15 (56) | |
Right | 14 (61) | 10 (37) | |
Bilateral | 0 (0/0) | 2 (7) | |
Multifocal lesions, No. (%) | 2 (9) | 6 (22) | 0.26 |
Eloquent location, No. (%) | 12 (52) | 23 (85) | 0.02 |
AED treatment, No. (%) | 15 (65) | 19 (70) | 0.70 |
Molecular subtypes, No. (%) | 0.56 | ||
IDHwt astrocytomas | 9 (39) | 7 (26) | |
IDHmut astrocytomas | 6 (26) | 10 (37) | |
Oligodendroglioma | 8 (35) | 10 (37) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Buvarp, D.; Rydén, I.; Sunnerhagen, K.S.; Olsson Bontell, T.; Gómez Vecchio, T.; Smits, A.; Jakola, A.S. Preoperative Patient-Reported Outcomes in Suspected Low-Grade Glioma: Markers of Disease Severity and Correlations with Molecular Subtypes. J. Clin. Med. 2021, 10, 645. https://doi.org/10.3390/jcm10040645
Buvarp D, Rydén I, Sunnerhagen KS, Olsson Bontell T, Gómez Vecchio T, Smits A, Jakola AS. Preoperative Patient-Reported Outcomes in Suspected Low-Grade Glioma: Markers of Disease Severity and Correlations with Molecular Subtypes. Journal of Clinical Medicine. 2021; 10(4):645. https://doi.org/10.3390/jcm10040645
Chicago/Turabian StyleBuvarp, Dongni, Isabelle Rydén, Katharina S. Sunnerhagen, Thomas Olsson Bontell, Tomás Gómez Vecchio, Anja Smits, and Asgeir Store Jakola. 2021. "Preoperative Patient-Reported Outcomes in Suspected Low-Grade Glioma: Markers of Disease Severity and Correlations with Molecular Subtypes" Journal of Clinical Medicine 10, no. 4: 645. https://doi.org/10.3390/jcm10040645